Research Article
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
Table 3
Summary of the ten most frequently reported treatment related toxicities.
| Adverse effect | Total (all grades) n (%) | Grade 3 or 4 n (%) |
| Alopecia | 69 (95.8) | 0 | Fatigue | 71 (98.6) | 2 (2.6) | Nausea | 49 (68.1) | 0 | Vomiting | 15 (20.8) | 1 (1.3) | Diarrhoea | 53 (73.6) | 2 (2.6) | Constipation | 41 (56.9) | 1 (1.3) | Mucositis | 50 (69.4) | 1 (1.3) | Palmar-planter syndrome | 23 (31.9) | 0 | Peripheral neuropathy | 40 (55.6) | 0 | Infection | 40 (55.6) | 4 (5.2) |
|
|